AHZ compared to Similar Stocks, page-52

Hi Dabru, it would be interesting to know what major entities have Admedus on its radar.

For a 'savvy' predator it would be, imo, a distinct commercial advantage to get in early and thus gain exposure to Admedus tech/IP at a way cheaper price than say in 2 or more years time.
Thus your concern, about a t/o anytime soon, imo, is justified.

I wonder IF any major entity is 'waiting' for Admedus to disinvest itself from its immunotherapies division, then make a move to either partner up or takeover, just a thought I had.

In ragards to ADAPT tech being applied to 'mesh' applications think that may be more than a few years away, Johnson & Johnson and American Medical systems dropped the ball badly on this one, I know because my Wife has been personally affected by the failure of this product.

That is one reason why Admedus has insisted on its trained staff to be at procedures involving its products with third parties so NO stuff ups happen and then blamed on its product .... that would be a disaster.